article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

Pharmaceutical companies and biotechs are also adapting their approaches, launching patient finding and engagement programmes that can start years before clinical trials begin and allow them to run ‘recontact by genotype’ studies that the Resilience Project would have liked to do. Giving participants something in return. About the author.

article thumbnail

Biorepositories as a Guiding Resource for Research & Drug Discovery

XTalks

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Generation of strong research dataset cohorts must begin with high-quality clinical samples. Partnerships and Establishing Research Cohorts.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How COVID-19 Has Permanently Changed The World of Medical Research

The Pharma Data

According to Nature Biotechnology, “81% of researchers are constrained by the inadequate quantity and quality of biospecimens and 80% of companies find accessing materials difficult.”. I think it’s also important to think about the definition of biobanks. It has made research more immediate. These are banks.

article thumbnail

Overcoming the Challenges of Sample Tracking in Clinical Trials with Blockchain Technology

Crucial Data Soutions

Step 2: escalating to jumping on the phone to talk live with the central lab, the bioanalytical lab, the sites, the biobank or anyone else in a quest to hunt down a specific sample. Blockchain technology provides increased security and traceability, two key components important to clinical research.